Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview of lecture
- Leprosy in 2021
- Geographical distribution of new leprosy cases, 2016
- ‘Big number’ leprosy countries in 2016
- Transmission
- M. Leprae within the new host
- Leprosy epidemiology (1)
- Leprosy epidemiology (2)
- Leprosy and HIV
- M. leprae
- Genetic susceptibility to leprosy
- M. leprae sequence
- Immune response to M. leprae
- Tuberculoid leprosy
- Lepromatous leprosy
- The anergy of the lepromatous patient
- Erythema nodosum leprosum (ENL)
- Pathogenesis of ENL
- Vaccines against leprosy
- What is disability?
- Progress of primary impairments
- Features of primary impairments
- POD interventions
- Self-care (SC)
- Components of self-care
- Mental health (MH)
- Footwear (dynamics)
- Insensible feet need good footwear
- Leprosy footwear
- Reconstructive surgery (RCS)
- COVID-19 and leprosy
- Leprosy services availability during COVID-19 pandemic
- COVID-19 overall implications
- Leprosy – new patients
- Leprosy web search
- New Face for Leprosy Project
- Patient experience (1)
- Patient experience (2)
- Achievements of New Face for Leprosy project
- The New Face for Leprosy
- New Face in India
- Patient experience (3)
- Patient experience (4)
- Patient experience (5)
- New Face – conclusions
- Thank you
- References
Topics Covered
- Epidemiology of leprosy
- Transmission global figures
- Leprosy and HIV
- M. leprae genome -Immune response in tuberculoid and lepromatous patients
- BCG vaccine and protection against leprosy
- Disability in leprosy
- Self-care and mental health in leprosy
- Footwear
- Covid and leprosy services
- New Face for leprosy
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Lockwood, D.N. (2024, July 23). Leprosy: epidemiology, pathology, immunology, prevention of disability and stigma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/HLKW3982.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Diana N.J. Lockwood has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Leprosy: epidemiology, pathology, immunology, prevention of disability and stigma
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
It's a pleasure to be doing the
second Henry Stewart lecture.
My name is Diana Lockwood,
and I'm an Emeritus Professor
of Tropical Medicine.
I've spent a lifetime
working in leprosy,
looking after patients
and trying to improve
outcomes for patients
combining clinical
work and research.
0:20
In this talk, I'm
going to talk about
the epidemiology of leprosy,
the pathology of leprosy,
because it's unique and
underlies the different
challenges of the disease.
The immunology is also
critical to the disease.
We don't yet really have
good vaccines for
preventing leprosy.
I'm going to talk about
the key part of managing
leprosy patients which is the
prevention of disability.
I'm also going to talk about
stigma, an old age problem,
and we've got new approaches
to challenging stigma.
0:52
In leprosy, as of 2021,
83% of the world's registered
cases are in 6 countries.
However, all the nations
report their leprosy
cases to WHO,
so we actually know
that patients have been
reported from 80 countries.
About 220,000 new cases
are detected annually.
The number of new cases
has been stable since
about 2007 and that's also
partly because of the
epidemiology of leprosy.
India, Brazil, Indonesia,
Tanzania and Ethiopia
are the top countries.
WHO has also identified 22
global priority countries
where leprosy is
deemed to be a problem
and they are in Africa,
Southeast Asia and Brazil.
Hide